Astral Systems, a pioneering fusion technology company based in Bristol, has successfully raised £23 million in its Series A funding round. This substantial investment, led by Mercia Ventures will be used to scale the production of radioactive isotopes essential for cancer diagnosis and treatment. Unlike many fusion companies focusing on future energy solutions, Astral Systems is already making a tangible impact in the medical field.
The global supply chain for medical isotopes is fragile and largely dependent on aging reactors in a few countries. This vulnerability was starkly highlighted in 2009 and 2010 when reactors in Canada and the Netherlands went offline simultaneously, causing severe shortages across Europe and North America. Astral Systems aims to address this critical gap by leveraging its innovative multi-state fusion technology to produce a reliable supply of isotopes.
Astral Systems’ Unique Approach to Fusion Technology
Astral Systems was founded in 2026 by Talmon Firestone and Tom Wallace-Smith. The company’s reactor design, known as multi-state fusion combines different fusion states in a single unit to produce intense neutron beams. These beams are then used to create isotopes. Unlike many fusion startups, Astral Systems is already operational, running three commercial fusion facilities and securing research contracts worth over £3 million.
The company is collaborating with McMaster University and a Brazilian nuclear research institute to develop two isotopes for targeted cancer therapy: Actinium-225 and Lead-212. Astral Systems aims to have at least one of these isotopes available on the market by early 2027.
The Strategic Move to Berkeley Power Station
With the new capital, Astral Systems plans to establish a site at the decommissioned Berkeley Power Station in Gloucestershire. This location offers significant advantages, including existing grid connections and nuclear-grade infrastructure. The company intends to operate several next-generation reactors at full capacity by the end of 2026, with a goal of achieving profitability in 2027. Astral Systems also plans to expand its workforce from 23 to over 40 employees.
To support this ambitious growth, Astral Systems has welcomed two senior scientists to its team: NASA Laureate Theresa Benyo as chief research officer and Mahmoud Bakr as chief scientist.
The Competitive Landscape and Future Prospects
Astral Systems is not the only company addressing the isotope shortage. In the United States, SHINE Technologies has raised over $1 billion and operates a large facility producing Lutetium-177. Another US-based company, Niowave uses electron accelerators for isotope production. However, neither of these companies serves the UK market directly.
Astral Systems argues that its technology can produce a wider range of isotopes at a modular scale, setting it apart from other fusion companies focused on future energy solutions. The global nuclear medicine market was valued at $17.77 billion in 2026 and is projected to reach $34.51 billion by 2030, according to Grand View Research.
“We are rewriting how we approach fusion and, in doing so, redefining what it means to be a fusion company,” said Firestone. Lee Lindley who led the deal at Mercia Ventures, described Astral Systems as “a perfect example of the bold ideas that Mercia likes to back.”
The success of Astral Systems could mark the beginning of a new era for British fusion technology, one that starts with cancer care rather than clean energy.
